TNNT2 and peripheral arterial disease: A 2021 study by Rammos et al. [27] found that among PAD patients aged ≥80 years, hs-cTnT provided significant prognostic information for all-cause mortality in a mean follow-up time of 12.5 years, suggesting its incorporation into risk assessment models for elderly PAD patients.